Abstract: Viruses having an impaired ability to deISGylate ISG15 conjugates, in particular, viral mutants comprising a mutation in the viral genome that reduces or eliminates the ability of the viral OTU domain-containing protein encoded by the viral genome to deISGylate ISG15 conjugates and/or deubiquitinate ubiquitinated proteins and/or deNeddylate Neddylated proteins are disclosed. Such viral mutants may be used in the formulation of immunogenic compositions for inducing an immune response and preventing, managing and/or treating a viral infection. Also disclosed are methods for identifying anti-viral compounds, in particular, methods of identifying compounds that reduce or inhibit the deISGylation activity and/or deubiquitination and/or deNeddylation activity of a viral OTU domain-containing protein. The compounds identified using such methods may be used as antiviral agents for the prevention, treatment and/or management of viral infections.

Abstract: Compositions and methods for inhibiting the growth of lens epithelial cells are provided. The compositions provided include a chelating agent in an amount sufficient for inhibiting the growth of lens epithelial cells. The compositions and methods provided may also be used for the treatment of disorders of the eye, especially in the treatment of presbyopia.

Abstract: Methods and compositions for medical imaging, evaluating intracellular processes and components, radiotherapy of intracellular targets, and drug delivery by the use of novel cell membrane-permeant peptide conjugate coordination and covalent complexes having target cell specificity are provided. Kits for conjugating radionuclides and other metals to peptide coordination complexes are also provided.

Abstract: Modified SH2 domains of intracellular proteins and methods of use, wherein the SH2 domains are modified to include an altered binding site for a signal transduction protein. The binding site is altered to either change the specificity of the SH2 domain for a signal transduction protein that is not the natural ligand or to include a reactive group, such as a reactive amino acid, that reacts with a phosphorylated amino acid of the signal transduction protein. The modified SH2 domains are useful as research tools or in methods for inactivating or inhibiting signal transduction proteins, especially those that contribute to disease or disorders such as cancer or for targeting specific SH2 domains for diagnostics.

Abstract: Monoclonal antibodies specific for an antigen present on the surface of parathyroid tissue are useful in imaging such tissue when conjugated to suitable label. The antibodies of the invention bind exclusively to parathyroid surfaces and do not bind to other tissues. The antibodies are useful in establishing the location of the parathyroid whether in its normal location or in ectopic placements. An exemplary monoclonal has been deposited at the American Type Culture Collection and has accession number ATCC No. HB9917.

Abstract: Monoclonal antibodies specific for an antigen present on the surface of parathyroid tissue are useful in imaging such tissue when conjugated to suitable label. The antibodies of the invention bind exclusively to parathyroid surfaces and do not bind to other tissues. The antibodies are useful in establishing the location of the parathyroid whether in its normal location or in ectopic placements. An exemplary monoclonal has been deposited at the American Type Culture Collection and has accession number ATCC No. HB9917.